Sugi Predict

Sugi Predict / Compounds / SCHEMBL1320844

SCHEMBL1320844

SCHEMBL1320844

CC(=O)c1c(O)ccc(F)c1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.52
▸ PRKCI P41743 1/20 0.43
▸ CA9 Q16790 2/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CES2 O00748 3/20 0.40
▸ CES1 P23141 3/20 0.40
▸ PKM P14618 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CA1 P00915 3/20 0.35
▸ CA2 P00918 3/20 0.35
▸ CA4 P22748 2/20 0.35
▸ CA12 O43570 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ HSD17B1 P14061 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30933133 1.00 THRB (0.52) THRBPRKCICA9MEN1CYP3A4
SCHEMBL31588491 0.84 THRB (0.54) THRBPRKCICA9MEN1CYP3A4
SCHEMBL1994723 0.84 CES2 (0.46) THRBMEN1CYP3A4HPGDKMT2A
SCHEMBL30313234 0.84 CES2 (0.46) THRBMEN1CYP3A4HPGDKMT2A
SCHEMBL24445882 0.83 THRB (0.46) THRBPRKCIMEN1CYP3A4HPGD
SCHEMBL12265429 0.83 THRB (0.52) THRBPRKCICA9MEN1CYP3A4
SCHEMBL24445654 0.81 THRB (0.50) THRBPRKCICA9MEN1CYP3A4
SCHEMBL30933127 0.80 CA1 (0.50) CA9MEN1HPGDKMT2ACES2
SCHEMBL17337217 0.80 CA1 (0.50) CA9MEN1HPGDKMT2ACES2
SCHEMBL5987066 0.79 THRB (0.48) THRBPRKCICA9MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4334298-B1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS INC (US) 2026-02-18 — — EP disclosed
US-20250250259-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2025-08-07 — — US disclosed
US-12312341-B2 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2025-05-27 — — US disclosed
US-20240400543-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-12-05 — — US disclosed
US-20240300939-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. 2024-09-12 — — US disclosed
US-12084434-B2 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2024-09-10 — — US disclosed
US-20240158376-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-05-16 — — US disclosed
CN-117813293-A Urea derivatives useful for the treatment of cancer 蝎子疗法股份有限公司 2024-04-02 — — CN disclosed
EP-4334298-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER Scorpion Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
US-20240076289-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-03-07 — — US disclosed
US-11897871-B1 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2024-02-13 — — US disclosed
WO-2022265993-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-12-22 — — WO disclosed
WO-2022265993-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-12-22 — — WO disclosed
US-8058447-B2 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-15 — — US disclosed
EP-1926727-B1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF Bayer Pharma AG (DE) 2011-09-14 — — EP disclosed
US-20090214675-A1 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof BAYER HEALTHCARE AG (DE) 2009-08-27 — — US disclosed
EP-1926727-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF Bayer HealthCare AG (DE) 2008-06-04 — — EP disclosed
WO-2007009670-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2007-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090214675-A1 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof RYR1, TNNI3, RYR2 THRB 2421/4885PRKCI 3091/4885CA9 2809/4885
US-20240300939-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER PIK3CA, PIK3CG, PIK3CD THRB 2942/4885PRKCI 48/4885CA9 2171/4885
US-20240158376-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 THRB 1210/4885PRKCI 45/4885CA9 1355/4885
US-11897871-B1 Methods for treating cancer PIK3CA, PTEN, BRCA1 THRB 1210/4885PRKCI 45/4885CA9 1355/4885
US-12312341-B2 Methods for treating cancer PIK3CA, PTEN, BRCA1 THRB 1210/4885PRKCI 45/4885CA9 1355/4885
US-20240076289-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 THRB 1210/4885PRKCI 45/4885CA9 1355/4885
US-20250250259-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 THRB 1210/4885PRKCI 45/4885CA9 1355/4885
US-20240400543-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 THRB 1210/4885PRKCI 45/4885CA9 1355/4885
US-12084434-B2 Methods for treating cancer PIK3CA, PTEN, BRCA1 THRB 1210/4885PRKCI 45/4885CA9 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.